Program
5% ASKC200
A development code. Also written as “1% ASKC200”.
Its studies are mostly in Osteoarthritis · Osteoarthritis, Knee, led by Beijing Aosaikang Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Aosaikang Pharmaceutical | 22 open or running | phase 2since Jul 26, 2026 | Sep 13, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2024First study: phase 1 study in Osteoarthritis, KneeFirst studyNCT06614608 · 24 planned · China
- Jul 26, 2026Phase 2 study in OsteoarthritisPhase 2 reachedNCT07742852 · 175 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07742852Osteoarthritis · China | 2 | Active, not recruiting | Apr 28, 2026 | 175 |
| NCT06614608Osteoarthritis, Knee · China | 1 | Not yet recruiting | Apr 2025 | 24 |
How it is read
Names in the registry
- “5% ASKC200”, 2 entries
- “1% ASKC200”, 2 entries
Codes read as this program: ASKC200.
Conditions, from the studies’ own filings
- Osteoarthritis, 1 study
- Osteoarthritis, Knee, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.